Vivek Ramaswamy’s Urovant claims a big win in PhIII — but questions linger about a cheap generic and their branded rival
After the great Axovant implosion that swept away its highly touted Alzheimer’s drug, Roivant chief Vivek Ramaswamy needed one of the biotechs in his fast-growing league of drug developers to win a big Phase III trial. Based on today’s top-line release for Urovant’s Phase III urinary incontinence drug vibegron, the team is claiming that victory and prepping an application for the FDA.
But there are some lingering questions about the cheap generic that was used as an active comparator in the study, and it’s driving the biotech’s stock into the red Tuesday morning.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.